搜尋結果
製品概要. ※ご使用にあたっては 電子添文 をご確認ください. 剤形名. メリスロン錠6mgの添付文書、インタビューフォームなどの情報を掲載しています。 エーザイの医療関係者向け情報サイトです。 医療用医薬品を適正にご使用いただくための情報を提供しています。
2024年3月29日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant ®
めまい・平衡障害治療剤; 総称名:メリスロン; 一般名:ベタヒスチンメシル酸塩; 販売名:メリスロン錠6mg, メリスロン錠12mg; 製造会社:エーザイ.
Internal. Revised: 11/2013. Effects of this medicine. This medicine relieves vertigo by increasing blood flow in inner ear. It is usually used in the treatment of vertigo due to Meniere's disease/syndrome. The following patients may need to be careful when using this medicine. Be sure to tell your doctor and pharmacist.
敏使朗（Merislon）是常見的頭暈藥，的用途、主要治療耳水不平衡的相關頭暈、耳鳴等症狀。 敏使朗止暈藥副作用是什麼？ 了解 Merislon效用及使用禁忌。
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
2022年11月7日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subs...
2024年3月30日 · Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon...
2022年11月7日 · TOKYO, Nov 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subsidiary of DKSH ...
